Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$0.39 - $0.71 $13,796 - $25,116
-35,376 Reduced 56.14%
27,639 $11,000
Q4 2022

Feb 09, 2023

SELL
$0.33 - $10.44 $15,003 - $474,654
-45,465 Reduced 41.91%
63,015 $25,000
Q3 2022

Nov 09, 2022

BUY
$0.92 - $11.16 $54,485 - $660,928
59,223 Added 120.23%
108,480 $92,000
Q2 2022

Aug 11, 2022

BUY
$1.02 - $1.83 $23,666 - $42,459
23,202 Added 89.05%
49,257 $57,000
Q1 2022

May 12, 2022

BUY
$1.06 - $2.1 $27,618 - $54,715
26,055 New
26,055 $37,000
Q3 2020

Nov 12, 2020

SELL
$1.11 - $1.68 $87,733 - $132,785
-79,039 Closed
0 $0
Q2 2020

Aug 13, 2020

SELL
$1.69 - $4.2 $53,289 - $132,434
-31,532 Reduced 28.52%
79,039 $136,000
Q1 2020

May 13, 2020

BUY
$1.26 - $3.38 $104,435 - $280,151
82,885 Added 299.38%
110,571 $292,000
Q4 2019

Feb 10, 2020

SELL
$0.86 - $1.44 $143,280 - $239,911
-166,605 Reduced 85.75%
27,686 $37,000
Q3 2019

Nov 12, 2019

BUY
$1.21 - $1.59 $14,288 - $18,776
11,809 Added 6.47%
194,291 $235,000
Q2 2019

Aug 09, 2019

BUY
$1.25 - $3.14 $196,312 - $493,137
157,050 Added 617.53%
182,482 $276,000
Q1 2019

May 13, 2019

SELL
$2.79 - $4.09 $31,460 - $46,118
-11,276 Reduced 30.72%
25,432 $75,000
Q4 2018

Feb 06, 2019

SELL
$3.23 - $7.01 $303,271 - $658,182
-93,892 Reduced 71.89%
36,708 $123,000
Q3 2018

Nov 08, 2018

BUY
$6.86 - $9.97 $569,716 - $827,998
83,049 Added 174.65%
130,600 $947,000
Q2 2018

Aug 14, 2018

BUY
$2.88 - $8.67 $128,701 - $387,444
44,688 Added 1560.88%
47,551 $327,000
Q1 2018

May 11, 2018

SELL
$2.92 - $3.81 $87,086 - $113,629
-29,824 Reduced 91.24%
2,863 $9,000
Q4 2017

Feb 09, 2018

SELL
$2.99 - $4.85 $59,477 - $96,476
-19,892 Reduced 37.83%
32,687 $100,000
Q3 2017

Nov 15, 2017

BUY
$3.01 - $5.41 $158,262 - $284,452
52,579
52,579 $247,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $1.09B
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.